Home > Boards > US OTC > Biotechs > Cytodyn Inc. (CYDY)

Biocon & Equillium

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
ombowstring Member Profile
 
Followed By 16
Posts 3,498
Boards Moderated 0
Alias Born 09/27/05
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 7/31/2020 5:21:59 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/24/2020 4:34:37 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 7/8/2020 5:07:43 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/8/2020 4:31:38 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/19/2020 5:19:36 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/8/2020 7:24:49 PM
Proxy Soliciting Materials (revised) (prer14a) Edgar (US Regulatory) - 6/8/2020 5:28:53 PM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 6/8/2020 6:02:50 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/2/2020 5:01:56 PM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 6/2/2020 8:01:17 AM
Amended Statement of Changes in Beneficial Ownership (4/a) Edgar (US Regulatory) - 5/15/2020 8:47:08 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 5/12/2020 6:00:59 AM
Securities Registration Statement (simplified Form) (s-3/a) Edgar (US Regulatory) - 4/30/2020 5:28:39 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/28/2020 5:29:47 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/27/2020 5:03:47 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/23/2020 5:08:55 PM
Amended Statement of Beneficial Ownership (3/a) Edgar (US Regulatory) - 4/22/2020 7:35:43 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/22/2020 5:38:33 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 4/22/2020 5:16:18 PM
The Next Hot Sector is Upon us and You Will Never Guess What It is InvestorsHub NewsWire - 4/16/2020 8:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 4/9/2020 4:45:19 PM
Other Filing Edgar (US Regulatory) - 4/9/2020 10:24:51 AM
Other Filing Edgar (US Regulatory) - 4/9/2020 10:24:21 AM
Amended Small Company Offering and Sale of Securities Without Registration (d/a) Edgar (US Regulatory) - 4/7/2020 10:48:57 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/6/2020 5:06:53 PM
ombowstring   Monday, 07/13/20 11:49:29 AM
Re: None
Post # of 103372 
Biocon & Equillium

https://www.biocon.com/biocon_press_release_20191212.asp

"Biocon & Equillium Expand Exclusive Licensing Agreement for Itolizumab to Include Australia and New Zealand

BENGALURU, Karnataka, India/ LA JOLLA, Calif. December 12, 2019 –

Biocon Ltd (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company and Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced that they have expanded their collaboration and license agreement for itolizumab to grant Equillium exclusive rights for developing and commercializing itolizumab in Australia and New Zealand.

Equillium had originally secured exclusive rights to develop and commercialize Biocon’s novel biologic, itolizumab, for the U.S. and Canada markets, in May 2017."

Apparently, EQ gets no money from sales in India. And they are way early in their clinical development, unless, I guess, the FDA gives them a Phase III.

https://equilliumbio.com/pipeline/#top

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist